Contact Supplier

Contact Supplier

To get in touch with ARTES Biotechnology GmbH, simply fill out the form below.

Subscribe to Supplier

Subscribe to Supplier


ARTES Biotechnology and Bio Farma to Collaborate on Vaccine Development

news-releasesARTES Biotechnology GmbH
July 31st 2013

The German biotechnology company ARTES and leading Indonesian vaccine manufacturer Bio Farma have announced they will join forces to develop and manufacture vaccine candidates.

The agreed collaboration will harness the respective strengths of both partners. ARTES specializes in cell line and process and VLP based vaccines development as well as in technology transfer for pharmaceutically relevant production processes. Bio Farma has complementary manufacturing strengths, being involved in the manufacturing of vaccines, serum and other biological products for the domestic Indonesian domestic as well as international markets.

The partnership was initiated with an initial agreement for VLP-based vaccine technology transfer, signed on July 1st in Bandung, Indonesia.

Dr. Michael Piontek, founder and managing director of ARTES Biotechnology, said: “We are extremely delighted about the mutually agreed collaboration. Bio Farma is a strong and reliable pharmaceutical partner and the only producer of human vaccines and antisera in Indonesia.”

“We are more than confident that in collaboration with Bio Farma, we will develop vaccines highly relevant for the Indonesian and neighboring markets. We expect that developments based on our Metavax® technology will make a special contribution to Bio Farma´s vaccine portfolio”. Dr. Piontek added.

Metavax® is a patent-protected virus-like particle (VLP) technology, based on the duck hepatitis B virus. The approach elicits a highly potent immune response and therefore a broader protection than currently available VLP approaches. The ARTES´ Metavax® platform is suitable for the development and production of safe and cost-effective vaccines.

The partnership is fully supported by the Indonesian Government, represented by the Ministry of Health, Ministry of Education and Culture and Ministry of Research and Technology. At the National Vaccine Research Forum, on 2-3 July 2013 in Jakarta, the ministries jointly delivered a commitment to develop policy to accelerate development of vaccines in Indonesia.

About ARTES Biotechnology GmbH
ARTES is a Germany-based biotechnology company specialized in recombinant protein production and process development from microbial expression systems. ARTES offers generation of optimized production cell lines in proprietary yeast expression systems based on Hansenula polymorpha. In addition to genetic engineering, the company provides fermentation and downstream process development, analytical assay development and production cell line characterization. ARTES operates worldwide from its 850 sqm S1 facilities in Langenfeld. The company focuses on the development of bio-similars and vaccines.

About Bio Farma
Bio Farma is Indonesia’s only vaccine and antisera producer for human. Currently, the needs for Expanded Program on Immunization (EPI) vaccines in Indonesia supplied solely by Bio Farma by manufacturing and distributing over 1.7 billion doses of vaccine annually to meet the needs of EPI vaccine in the national immunization program. Bio Farma has an outstanding international reputation based on the WHO prequalification for all of its EPI vaccine products. Its products are exported to countries worldwide through direct distribution or various agencies such as UNICEF. Bio Farma has obtained the Best Export Performance from the Trade Ministry of Indonesia in the last three years up to 2012 as an evidence of its consistent exceptional performance.

For more information about ARTES Biotechnology and Bio Farma to collaborate on vaccine development please contact ARTES Biotechnology directly.

Contact ARTES Biotechnology GmbH

Simply fill out the form below to contact ARTES Biotechnology GmbH now.

Send ARTES Biotechnology GmbH a Message